1.Radiation Therapy Oncology Group (RTOG) Semi-Annual Meeting
Tampa, Florida
February 3, 2007
2.Urban Latino African American Cancer (ULAAC) Disparities Project
Michael L. Steinberg, MD, FACR
Principal Investigator
David Huang, MD
Co-Investigator
Nicole Harada, CCRC, CCRP
Clinical Trials Coordinator/Data Manager
3.Component Updates
Administrative
Navigation
Clinical Trials
Telesynergy/Telemedicine
Quality Assurance
Publications, Articles, and Presentations
Work in Progress
4.Administrative Component
5.Our Partners
Centinela Freeman Regional Medical Center
Michael L. Steinberg, MD, FACR, Principal Investigator
David Khan, MD, Co-Investigator
David Huang, MD, Co-Investigator
RAND Corporation
Allen Fremont, MD, PhD
Nell Forge, PhD , Co-Investigator
USC Norris Comprehensive Cancer Center
Oscar Streeter, MD , Co-Investigator
UCSF Comprehensive Cancer Center
Mack Roach, MD , Co-Investigator
6.Infrastructure
Project Staff:
Debbie Karaman, MPH, Community Health Educator
Erika Cobb, Program Administrative Assistant
Herschel Knapp, PhD, MSSW
Nicole Harada, Clinical Trials Coordinator
Susan Richardson, RN, Oncology Nurse
Keith Andre, MA, Project Administrator
7.Community Liaison
Community Advisory Board
Meets two times per year
Investigators’ Meeting
Meets two times per year
Medical Advisory Board
Meets 6 times per year
8.Navigation Component
9.Our Patients
10.Abnormal results
Diagnosis
Treatment
ConcludeNavigation
Cancer Disparities Research Partnership (CDRP)
Patient Navigation Model
Outreach
Patient Navigation
Rehabilitation
Abnormal Results
Diagnosis
Treatment
Abnormal Finding
Resolution
ConcludeNavigation
Freeman, et.al., Cancer Practice, 1995.
Cancer Diagnosis
11. Patient Navigator Training Program
The 9-hour navigator training course emphasizes:
Investigating and implementing resources for patients in a timely fashion
Listening compassionately and non-judgmentally
Completing appropriate records of all interactions on behalf of patient
Empowering patients to self-advocate in the healthcare realm
12.Training Program
13.Active Navigators
14.Reasons for Navigator Attrition
15.Gender of Active Navigators
16.Ethnicity of Active Navigators
17.Cancer Survivor Status of Active Patient Navigators
18.Patient Data
19.Patients Offered Navigation By Project Year
20.Ethnicity of Patients Offered Navigation
21.Percentage of each Ethnicity Accepting Navigation
* Small sample size
22.Percentage of Patients Accepting NavigationBy Ethnicity
23.Measuring the Effectiveness of Barrier Solution Identification
Patient-specific barriers to care are identified during the patient intake conducted by a navigator
Records are maintained and audited to determine number of days to barrier solution identification
Barrier solution includes assigning a navigator (psychosocial barriers) and identifying community resources (functional barriers)
24.Premise
Barriers to care increase the likelihood that the patient will not be able to comply with treatment and follow-up regimens
Barriers to care increase the likelihood that the patient will not participate in a clinical trial
Addressing barriers to care will increase compliance and likelihood of clinical trials participation
25.6 Most Common Barriers
26.Barriers to Care: Chart Audit
27.Mean Number of Days to Barrier Solution Identification
28.Percentage of Barriers Solutions Identified in One Day
29.Clinical Trials
30.Trials Open for Accrual
31.Trials Closed to Accrual
32.Patients Accrued to Trial
33.Accrual to Trial by Ethnicity
34.Clinical Trial Accrual/Navigation
35.Telesynergy/Telemedicine
36.Telesynergy Telemedicine
37.Telesynergy Usage
Tumor Boards
Meetings with partners and mentoring institutions
Meetings with CDRP sites
38.Quality Assurance
39.
40.
41.Instruments
*Patient Satisfaction Survey
*Cancer Post Treatment Survey
*Clinical Trial Questionnaire
Rand Process Instrument – In Process
42. 1. The patient navigator was courteous. 2. The patient navigator was sensitive. 3. The patient navigator was respectful. 4. The patient navigator was friendly. 5. The patient navigator was thorough. 6. I valued working with the navigator. 7. The education materials I received were helpful. 8. Support services referrals met my needs. 9. I received financial information (if needed).10. I would recommend this service to others.Response: 5 point Likert Scale Strongly Agree = 5, Strongly Disagree = 1 N/A option offered on each question
Patient Satisfaction Survey
43.Sample method
Each month, 10% of patients are randomly selected for telephone navigator service satisfaction survey.
44.Q: Does the navigator’s cancer history predict patient satisfaction?
In other words:
Do you have to have had cancer in order to provide effective cancer navigation?
45.Navigators without a hx. of CA outperformed navigators w/ CA hx. on 60% of patient satisfaction metrics.
46.Statistically Significant Differences
Individual ANOVA test revealed a statistically significant difference on question 7 (only).
47.
Overall patient satisfaction exceeds 90% with navigator services regardless of navigator’s cancer history (p = .953).
Note: 5-point Likert scale scores presented as satisfaction percentages
48.Would you like to continue with the Patient Navigator Program?
I would like to continue working with my navigator.
I would like to have a different navigator assigned to me.
I would like to discontinue receiving navigation.
Final Question on Survey
49.94.7% of patients surveyed chose to continue navigation.
Navigator’s CA hx. does not predict patient satisfaction (X2: p = .329.)
50.Provisional Findings
Overall, there is no statistically significant difference in patient satisfaction when comparing navigators who have had cancer to navigators who have not had cancer.
In other words:
All helping hands are good hands and 95% of patients were satisfied and wished to continue navigation
54.Reasons for refusing navigation
85% I am an independent person
68% I have a supportive family
47% I am a private person
44% I have supportive friend(s)
42% I am a spiritual / religious person
23% Navigation seemed unnecessary
13% I was unclear on what the navigator would do
8% The role of the navigator seemed intrusive to me
55.Demographics
No significant differences (p > .05)
Race
Education
Religion
Marital status
Living conditions
Income
56.Treatment Satisfaction
No significant differences (p > .05) on 8 of 9 metrics using a 1 – 4 Likert scale (1 = never, 4 = always):
During my cancer treatment, I had good communication with my care providers.
Accepted navigation: 2.85
Refused navigation: 2.54
(p = .037)
}
57.FACIT instrument
Physical 7 questions
Social / Family 7 questions
Emotional 6 questions
Functional 7 questions
Spiritual 12 questions
Patient self-evaluation multi-scale instrument
Measures 5 areas of well being using 5 point Likert scales (1 = not at all, 5 = very much)
58.FACIT Scores
No significant differences (p > .05) on 3 of 5 scales:
Physical
Social / Family
Spiritual
60.Do Navigators Make a Difference in Acceptance of Clinical Trials?
Challenges:
Small n
the reality of the number of patients eligible for clinical trial in a community hospital
process change required to ensured the early presence of a navigator in CT discussions
61.Do Navigators Make a Difference in Acceptance of Clinical Trials?
Preliminary impressions suggest that early inclusion of a navigator in discussions with patients about clinical trials is associated with an increase rate of participation
62.Do Navigators Make a Difference in Acceptance of Clinical Trials?
Of patients eligible for a trial who have a navigator present at CT discussions
80% accept
20% decline
n = 5
Only 1*/9 pts who declined had navigator input
* perception of non coverage by insurance
(managed care)
63."Will get closer follow-up" as primary reason for patient accepting CT (navigator observation)
Patients who accepted CT with a navigator present at CT discussions gave as stated reason for acceptance
Of eligible patients who do not have a
navigator present at CT discussions:
0% give “Will get closer follow up” as their primary reason for participating
64.Presentations, Articles, and Publications
65. Publications
Lay Patient Navigator Program Implementation For Equal Access To Cancer Care And Clinical Trials: Essential Steps And Initial Challenges
Cancer, Volume 107, Issue 11 , Pages 2669 – 2677
Preliminary results and evaluation of MammoSite® balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: A phase II clinical study
In press, The American Journal of Surgery
66.Presentations
“National Leadership Summit on Eliminating Racial Disparities in Health”
January 9-11, 2006 Washington, D.C.
“Prophylactic Post-Operative Antibiotics for Prostate Brachytherapy”
Presented at the 2006 Prostate Cancer Symposium at ASCO in 2006
67.Presentations
Preliminary results and evaluation of MammoSite® balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: A phase II clinical study
Presented at the American Society of Breast Surgeons Meeting, April 2006
Developing a Lay Patient Navigator Program Addressing Barriers to Care and Participation in Clinical Trials
Presented at the Cancer REACH 2010 Conference, May 2006
Using Telesynergy® to Improve Access to Clinical Trials at an Underserved Community Based Hospital
Submitted to ASTRO, November 2006
68.Presentations
The Use of Lay Patient Navigators to Improve Quality of Care and Accrual to Clinical Trials for Radiation Oncology Patients Who Are Minorities or of Low Socioeconomic Status
Presented at ASTRO 2006, Philadelphia, PA, Nov. 5-9, 2006
Do Navigators Make a Difference in Acceptance of Clinical Trials?
Presented at ASTRO 2006, Philadelphia, PA, Nov. 5-9, 2006
Disparity in Cancer Treatment and Outcome
Presented at Mid-Winter Oncology Meeting, Los Angeles, Ca. Jan 23,2007
69.Poster Presentations
A Lay Patient Navigator Program as Part of a Clinical Trials Infrastructure in a Community Hospital Serving Minority and Low Income Patients
Poster Presentation at the Cancer Health Disparities Summit 2006, Bethesda, MD, July 17-19, 2006
Lay patient navigator program for equal access to cancer care and clinical trials
Poster presentation at ASTRO Health Services/Outcomes Research In Radiation Oncology, San Diego, CA September 15, 2006
70.Work in Progress
71.Work in Progress
Spanish Support Group:
To provide comfort, support, and education for Latinos undergoing cancer treatment in the community
Susan B. Komen Foundation Grant:
To train monolingual Latino navigators for the Breast Center at Centinela Campus, to help Spanish-speaking women access resources for treatment, to establish continuity of care, and to promote annual screening
NCCCP:
To establish a comprehensive cancer center of excellence and to incorporate navigation in medical oncologists’, pathologists’, and surgeons’ medical practices to facilitate pre-treatment barrier reduction
72.Work in Progress
Relocation of ULAAC Office to Centinela Campus:
To capture oncology patients for navigation and to help them access resources for treatment
Telesynergy/Telemedicine:
To relocate to Centinela Campus for better utilization
HRSA Nursing Workforce Grant:
To train nurses of all discipline to close the shortage gap. Also to encourage professional nurses to enhance and refine their training and education
73.
Disparity is about Poverty
and
Lack of Infrastructure
designed to
Deal With the Indigent Patient’s Needs
74.Contact Us
Urban Latino African American Cancer (ULAAC) Disparities Project
at Centinela Freeman Regional Medical Center, Memorial Campus
333 North Prairie AvenueInglewood, CA 90301
Telephone: (310) 674-7050, extension 4661
Fax: (310) 671-8299
Email: mls@cccma.com
Principal Investigator: Michael L. Steinberg, MD, FACR